as 03-12-2025 1:33pm EST
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | BRISBANE |
Market Cap: | 1.1B | IPO Year: | 2014 |
Target Price: | $29.43 | AVG Volume (30 days): | 950.5K |
Analyst Decision: | Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.93 | EPS Growth: | N/A |
52 Week Low/High: | $7.42 - $34.84 | Next Earning Date: | 05-08-2025 |
Revenue: | $333,785,000 | Revenue Growth: | 19.07% |
Revenue Growth (this year): | 13.32% | Revenue Growth (next year): | 14.99% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Novack Jeffrey Adam | CDNA | Secretary and General Counsel | Feb 3 '25 | Sell | $23.30 | 3,512 | $81,829.25 | 104,677 |
CDNA Breaking Stock News: Dive into CDNA Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Simply Wall St.
5 days ago
Zacks
8 days ago
GuruFocus.com
14 days ago
Zacks
14 days ago
Associated Press Finance
14 days ago
Business Wire
14 days ago
GuruFocus.com
15 days ago
The information presented on this page, "CDNA CareDx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.